What is Positron?
Positron operates at the intersection of medical technology and diagnostic innovation. The company specializes in the development of sophisticated imaging systems, most notably the NeuSight PET-CT, which is engineered to address the critical needs of modern cardiology departments. By focusing on reducing scan times and enhancing image resolution, Positron provides healthcare providers with the tools necessary to improve patient outcomes. The company's market position is defined by its commitment to clinical excellence and the integration of high-precision hardware into routine cardiac diagnostics, effectively bridging the gap between complex molecular imaging and practical, high-volume clinical application.
How much funding has Positron raised?
Positron has raised a total of $305.1M across 3 funding rounds:
Seed
$23.5M
Series A
$51.6M
Series B
$230M
Seed (2025): $23.5M with participation from Valor Equity Partners, Flume Ventures, and Atreides Management
Series A (2025): $51.6M led by Valor Equity Partners, DFJ Growth, Unless, Atreides Management, Flume Ventures, and 1517 Fund I
Series B (2026): $230M supported by Flume Ventures, DFJ Growth, Jump Trading, Valor Equity Partners, and Unless
Key Investors in Positron
Valor Equity Partners
Valor Equity Partners is a Chicago-based investment firm established in 2001, providing comprehensive financial services and strategic capital to businesses across various growth stages.
Flume Ventures
Flume Ventures is a network of seasoned operators and founders that partners with visionary entrepreneurs to scale bold ideas through mentorship and strategic community support.
DFJ Growth
DFJ Growth is a global venture capital firm founded in 2005, specializing in providing late-stage capital to rapidly scaling technology companies poised for market leadership.
What's next for Positron?
With the successful completion of this major enterprise-level funding, Positron is entering a critical phase of commercial expansion and technological refinement. The company is expected to utilize these resources to scale its manufacturing capabilities and broaden the distribution of its imaging platforms across global healthcare markets. Furthermore, the strategic backing from a diverse group of investors suggests a focus on long-term growth, potentially involving the development of next-generation diagnostic software and the expansion of clinical support services. As Positron continues to navigate the competitive landscape of medical imaging, the focus will likely remain on maintaining its technological edge while driving the widespread adoption of PET imaging in cardiology.
See full Positron company page
